Fig. 1From: Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United KingdomQuarterly Change in Proportions of First-line Use for Each Drug Class Over Study Observation Period. ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; Q, quarterBack to article page